Cas:5770-40-1 1,3-dibutyl-1,3-diazinane-2,4,6-trione manufacturer & supplier

We serve Chemical Name:1,3-dibutyl-1,3-diazinane-2,4,6-trione CAS:5770-40-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

1,3-dibutyl-1,3-diazinane-2,4,6-trione

Chemical Name:1,3-dibutyl-1,3-diazinane-2,4,6-trione
CAS.NO:5770-40-1
Synonyms:1,3-dibutyl-pyrimidine-2,4,6-trione;dibutylbarbituric acid;N,N’-dibutylbarbituric acid;1,3-Dibutylbarbituric acid
Molecular Formula:C12H20N2O3
Molecular Weight:240.29900
HS Code:2933540000

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:57.69000
Exact Mass:240.14700
LogP:1.64330

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 1,3-dibutyl-pyrimidine-2,4,6-trione chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,1,3-Dibutylbarbituric acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N,N’-dibutylbarbituric acid Use and application,N,N’-dibutylbarbituric acid technical grade,usp/ep/jp grade.


Related News: So-called “off” periods occur when a Parkinson’s patient has difficulty moving about and occur when the effect of the last dose of another common Parkinson’s drug, known as levodopa, wears off. Z-L-Pro-D-Ala-OEt manufacturers Officials did, however, acknowledge that there’s growing evidence an extra jab may enhance the antibody response in immunocompromised people. Some small studies suggest up to 50% of people with no antibody response after the authorized regimen of two mRNA jabs developed a response after an additional dose, said CDC’s Sara Oliver, M.D. 2,5-Pyrrolidinedione, 1-[(1H-benzotriazol-5-ylcarbonyl)oxy]- suppliers “This announcement reflects another important regulatory milestone in the development of this medicine,” said Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. 9-(1,2,5-trimethylpiperidin-4-yl)-9H-fluoren-9-ol vendor & factory.